Translating MSC Therapy in the Age of Obesity

Mesenchymal stromal cell (MSC) therapy has seen increased attention as a possible option to treat a number of inflammatory conditions including COVID-19 acute respiratory distress syndrome (ARDS). As rates of obesity and metabolic disease continue to rise worldwide, increasing proportions of patient...

Full description

Bibliographic Details
Published in:Frontiers in Immunology
Main Authors: Lauren Boland, Laura Melanie Bitterlich, Andrew E. Hogan, James A. Ankrum, Karen English
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Subjects:
mesenchymal stromal cells (MSCs)
disease microenvironment
obesity
immunomodulation
metabolic disease
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.943333/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.943333/full

Similar Items